Clinical proteomics in cancer research

Current Proteomics

Volumn 10, Issue 2, 2013, Pages 179-191

  López, Elena ^a   Madero, Luis ^a   Melén, Gustavo J ^a   Ramírez, Manuel ^a   Roukos, Dimitrios H ^b,c   Cho, William C ^d  

^a HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

^d Department of Clinical Oncology Queen Elisabeth Hospital   (Hong Kong)

Author keywords

Cancer; Clinical proteomics; Omics; Personalized medicine

Indexed keywords

APOLIPOPROTEIN E; CA 195 ANTIGEN; CLUSTERIN; INTERCELLULAR ADHESION MOLECULE 1; LEGUMAIN; PROSTAGLANDIN D2 SYNTHASE; PROSTAGLANDIN SYNTHASE; RAC2 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER PROGNOSIS; CANCER RESEARCH; CANCER RESISTANCE; CARCINOGENESIS; DRUG RESPONSE; DRUG TARGETING; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; PROTEOMICS; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84882802198     PISSN: 15701646     EISSN: None     Source Type: Journal    
DOI: 10.2174/15701646112099990001     Document Type: Article

References (176)

1. Kettenbach AN, Gerber SA. Rapid and reproducible single-stage Kettenbach, A.N. and Gerber, S.A. Rapid and reproducible single-stage phosphopeptide enrichment of complex peptide mixtures: application to general and phosphotyrosine-specific phosphopro-teomics experiments. Anal. Chem., 2011, 83(20), 7635-7644.
2. Wright, P.C.; Noirel, J.; Ow, S.Y. and Fazeli, A. A review of current proteomics technologies with a survey on their widespread use in reproductive biology investigations. Theriogenol., 2012, 77(4), 738-765.
3. Zhong, Y.; Hyung, S.J. and Ruotolo, B.T. Ion mobility-mass spec trometry for structural proteomics. Expert. Rev. Proteomics, 2012, 9(1), 47-58.
4. Schirle, M.; Bantscheff, M. and Kuster, B. Mass spectrometry based proteomics in preclinical drug discovery. Chem. Biol., 2012, 19(1), 72-84.
5. Bouwman, J.; Vogels, J.T.; Wopereis, S.; Rubingh, C.M.; Bi jlsma, S. and van Ommen, B. Visualization and identification of health space, based on personalized molecular phenotype and treatment response to relevant underlying biological processes. BMC Med. Genomics, 2012, 5, 1.
6. Catusse, J.; Meinhard, J.; Job, C.; Strub, J.M.; Fischer, U.; Pest sova, E.; Westhoff, P.; Van Dorsselaer, A. and Job, D. Proteomics reveals potential biomarkers of seed vigor in sugarbeet. Pro-teomics, 2011, 11(9), 1569-1580.
7. López, E.; Wesselink, J.J.; López, I.; Mendieta, J.; Gómez Puertas, P. and Muñoz, S.R. Technical phosphoproteomic and bio-informatic tools useful in cancer research. J. Clin. Bioinforma, 2011, 1, 26.
8. López, E.; López, I.; Sequí, J. and Ferreira, A. Discovering and validating unknown phospho-sites from p38 and HuR protein kinases in vitro by phosphoproteomic and bioinformatic tools. J. Clin. Bioinforma, 2011, 1(1), 16.
9. López, E.; López, I.; Ferreira, A. and Sequí, J. Clinical and tech-nical phosphoproteomic research. Proteom. Sci., 2011, 9, 27.
10. Lodish, H.; Berk, A.; Zipursky, S.L.; Matsudaira, P.; Baltimore, D. and Darnell, J. WH Freeman and Company, Molecular Cell Biology 2002, Fouth Edition.
11. Mandong, B.M. and Ngbea, J.A. Cancer prevention strategies. Niger J. Med., 2011, 20(4), 399-405.
12. Ectors, N. And Verh, K. International and national initiatives in biobanking. Acad. Geneeskd. Belg., 2011, 73(1-2), 5-40.
13. Semiglazova, Tiu.; Semiglazov, V.V.; Filatova, L.V.; Gershanovich, M.L.; Chudenko, V.A.; Latipova, DKh.; Luk'Ianchikova, V.S.; Dashian, G.A. and Paltuev, R.M. Novel target therapies used in breast cancer management. Vopr. Onkol., 2011, 57(5), 592-600.
14. Ostapenko, V. and Ostapenko, A. Significance and specifics of surgical treatment in locally advanced breast cancer. Vopr. Onkol., 2011, 57(5), 578-583.
15. Junker, A. Cancer treatment in the elderly. Med Monatsschr Pharm., 2011, 34(12), 462-464.
16. Ozkan, S.; Ozkan, M. and Armay, Z. Cultural meaning of cancer suffering. J. Pediatr. Hematol. Oncol., 2011, 33(Suppl 2), S102-S104.
17. Anderson, N.L. and Anderson, N.G. Proteome and proteomics: new technologies, new concepts, and new words. Electrophoresis, 1998, 19(11), 1853-1861.
18. Blackstock, W.P. and Weir, M.P. Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol., 1999, 17(3), 121-127.
19. James, P. Protein identification in the post-genome era: the rapid rise of proteomics. Quart. Rev. Biophys., 1997, 30(4), 279-331.
20. Wilkins, M.R.; Pasquali, C.; Appel, R.D.; Ou, K.; Golaz, O.; Sanchez, J.C.; Yan, J.X.; Gooley, A.A.; Hughes, G.; Humphery-Smith, I.; Williams, K.L. and Hochstrasser, D.F. From Proteins to Proteomes: Large Scale Protein Identification by Two-Dimensional Electrophoresis and Arnino Acid Analysis. Nat. Bio-technol., 1996, 14(1), 61-65.
21. Thomson, J.J. Rays of Positive Electricity and Their Implication to Chemical Analysis. Longmans Green, London. 1913.
22. Etzioni, R.; Urban, N.; Ramsey, S.; McIntosh, M.; Schwartz, S.; Reid, B.; Radich, J.; Anderson, G. and Hartwell, L. The case for early detection. Nat. Rev. Cancer, 2003, 3, 243-252.
23. Anderson, L. Candidate-based proteomics in the search for bio markers of cardiovascular disease. J. Physiol., 2005, 563, 23-60.
24. Rifai, N.; Gillette, M.A. and Carr, S.A. Protein biomarker discov-ery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol., 2006, 24, 971-983.
25. García-Foncillas, J.; Bandrés, E.; Zárate, R. and Remírez, N. Proteomic analysis in cancer research: potential application in clinical use. Clin. Transl. Oncol., 2006, 8, 250-261.
26. Bouchal, P.; Roumeliotis, T.; Hrstka, R.; Nenutil, R.; Vojtesek, B. and Garbis, S.D. Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis. J. Proteom. Res., 2009, 8, 362-373.
27. Wiener, M.C.; Sachs, J.R.; Deyanova, E.G. and Yates, N.A. Dif-ferential mass spectrometry: a label-free LC-MS method for finding significant differences in complex peptide and protein mixtures. Anal. Chem., 2004, 76, 6085-6096.
28. Geiger, T.; Cox, J.; Ostasiewicz, P.; Wisniewski, J.R. and Mann, M. Super-SILAC mix for quantitative proteomics of human tumor tissue. Nat. Methods, 2010, 7, 383-385.
29. Anderson, L. and Hunter, C.L. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell Proteomics, 2006, 5, 573-588.
30. Wang, H.; Wong, C.H.; Chin, A.; Kennedy, J.; Zhang, Q. and Hanash, S. Quantitative serum proteomics using dual stable isotope coding and nano LC-MS/MSMS. J. Proteome Res., 2009, 8, 5412-5422.
31. Lee, J.; Soper, S.A. and Murray, K.K. Microfluidic chips for mass spectrometry-based proteomics. J. Mass Spectrom., 2009, 44, 579-593.
32. Pierobon, M.; Calvert, V.; Belluco, C.; Garaci, E.; Deng, J.; Lise, M.; Nitti, D.; Mammano, E.; Marchi, F.D.; Liotta, L. and Petri-coin, E. Multiplexed cell signaling analysis of metastatic and nonmetastatic colorectal cancer reveals COX2-EGFR signaling activation as a potential prognostic pathway biomarker. Clin. Co-lorectal Cancer, 2009, 8, 110-117.
33. Ramachandran, N.; Raphael, J.V.; Hainsworth, E.; Demirkan, G.; Fuentes, M.G.; Rolfs, A.; Hu, Y. and LaBaer, J. Next-generation high-density self-assembling functional protein arrays. Nat. Methods, 2008, 5, 535-538.
34. Beirne, P.; Pantelidis, P.; Charles, P.; Wells, A.U.; Abraham, D.J.; Denton, C.P.; Welsh, K.I.; Shah, P.L.; du Bois, R.M. and Kelle-her, P. Multiplex immune serum biomarker profiling in sarcoido-sis and systemic sclerosis. Eur. Respir. J., 2009, 34, 1376-1382.
35. Kelleher, M.T.; Fruhwirth, G.; Patel, G.; Ofo, E.; Festy, F.; Barber, P.R.; Ameer-Beg, S.M.; Vojnovic, B.; Gillett, C.; Coolen, A.; Kéri, G.; Ellis, P.A. and Ng, T. The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients. Target Oncol., 2009, 4, 235-252.
36. Wang, P.; Whiteaker, J.R. and Paulovich, A.G. The evolving role of mass spectrometry in cancer biomarker discovery. Cancer Biol. Ther., 2009, 8, 1083-1094.
37. Whiteaker, J.R.; Zhang, H.; Eng, J.K.; Fang, R.; Piening, B.D.; Feng, L.C.; Lorentzen, T.D.; Schoenherr, R.M.; Keane, J.F.; Holzman, T.; Fitzgibbon, M.; Lin, C.; Zhang, H.; Cooke, K.; Liu, T.; Camp, D.G. 2nd, Anderson, L.; Watts, J.; Smith, R.D.; McIn-tosh, M.W. and Paulovich, A.G. Head-to-head comparison of serum fractionation techniques. J. Proteom. Res., 2007, 6, 828-836.
38. Ernoult, E.; Bourreau, A.; Gamelin, E. and Guette, C. A proteo mic approach for plasma biomarker discovery with iTRAQ labeling and OFFGEL fractionation. J. Biomed. Biotechnol., 2010, 2010, 927917.
39. Nirmalan, N.J.; Hughes, C.; Peng, J.; McKenna, T.; Langridge, J.; Cairns, D.A.; Harnden, P.; Selby, P.J. and Banks, R.E. Initial development and validation of a novel extraction method for quantitative mining of the formalin-fixed, paraffin-embedded tissue pro-teome for biomarker investigations. J. Proteom. Res., 2010, 10, 896-906.
40. Krishhan, V.V.; Khan, I.H. and Luciw, P.A. Multiplexed mi crobead immunoassays by flow cytometry for molecular profiling: basic concepts and proteomics applications. Crit. Rev. Biotech-nol., 2009, 29, 29-43.
41. Cha, S.; Imielinski, M.B.; Rejtar, T.; Richardson, E.A.; Thakur, D.; Sgroi, D.C. and Karger, B.L. In situ proteomic analysis of human breast cancer epithelial cells using laser capture microdis-section: annotation by protein set enrichment analysis and gene ontology. Mol. Cell Proteomics, 2010, 9, 2529-2544.
42. Anderson, K.S.; Sibani, S.; Wallstrom, G.; Qiu, J.; Mendoza, E.A.; Raphael, J.; Hainsworth, E.; Montor, W.R.; Wong, J.; Park, J.G.; Lokko, N.; Logvinenko, T.; Ramachandran, N.; Godwin, A.K.; Marks, J.; Engstrom, P. and Labaer, J. Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J. Proteom. Res., 2011, 10, 85-96.
43. Bateman, N.W.; Sun, M.; Hood, B.L.; Flint, M.S. and Conrads, T.P. Defining central themes in breast cancer biology by differential proteomics: conserved regulation of cell spreading and focal adhesion kinase. J. Proteome Res., 2010, 9, 5311-5324.
44. 18O-labeling to identify biomarkers for cholangiocarcinoma. J. Proteome Res., 2008, 7, 4670-4677.
45. An, H.J. and Lebrilla, C.B. A glycomics approach to the discovery of potential cancer biomarkers. Methods Mol. Biol., 2010, 600, 199-213.
46. Choudhary, C. and Mann, M. Decoding signalling networks by mass spectrometry-based proteomics. Nat. Rev. Mol. Cell. Biol., 2010, 11, 427-439.
47. Madian, A.G. and Regnier, F.E. Profiling carbonylated proteins in human plasma. J. Proteome Res., 2010, 9, 1330-1343.
48. Iwabata, H.; Yoshida, M. and Komatsu, Y. Proteomic analysis of organ-specific post-translational lysine-acetylation and-methylation in mice by use of anti-acetyllysine and-methyllysine mouse monoclonal antibodies. Proteomics, 2005, 5, 4653-4664.
49. Ceroni, A.; Sibani, S.; Baiker, A.; Pothineni, V.R.; Bailer, S.M.; LaBaer, J.; Haas, J. and Campbell, C.J. Systematic analysis of the IgG antibody immune response against varicella zoster virus (VZV) using a self-assembled protein microarray. Mol. Biosyst., 2010, 6, 1604-1610.
50. Wong, J.; Sibani, S.; Lokko, N.N.; LaBaer, J. and Anderson, K.S. Rapid detection of antibodies in sera using multiplexed self-assembling bead arrays. J. Immunol. Methods, 2009, 350, 171-182.
51. Anderson, N.L. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin. Chem., 2010, 56, 177-185.
52. Osterfeld SJ, Yu H, Gaster RS, Caramuta S, Xu L, Han SJ, Hall, D.A.; Wilson, R.J.; Sun, S.; White, R.L.; Davis, R.W.; Pourmand, N. and Wang, S.X. Multiplex protein assays based on real-time magnetic nanotag sensing. Proc. Natl. Acad. Sci. USA, 2008, 105, 20637-20640.
53. Jensen, O.N. Phosphoproteomics: mass spectrometry based tech niques for systematic phosphoprotein analysis. In Proteome Analysis, Elsevier Science, 2004, 139-162.
54. Hubbard, M.J. and Cohen, P. On target with a new mechanism for the regulation of protein-phosphorylation trends. Biochem. Sci., 1993, 18, 172-177.
55. Stryer, L. WH Biochemistry. Freeman and Company, 1995, Fourth Edition.
56. Mann, M.; Ong, S.E.; Gronborg, M.; Steen, H.; Jensen, O.N. and Pandey, A. Analysis of protein phosphorylation using mass spec-trometry: deciphering the phosphoproteome. Trends Biotechnol., 2002, 20(6), 261-268.
57. Mann, M. and Jensen, O.N. Proteomic analysis of post translational modifications. Nat. Biotechnol., 2003, 21(3), 255-261.
58. Yarbro, J.W. Oncogenes and cancer suppressor genes. Semin. Oncol. Nurs., 1992; 8(1), 30-39.
59. Thingholm, T.E.; Jensen, O.N.; Robinson, P.J. and Larsen, M.R. SIMAC (sequential elution from IMAC), a phosphoproteomics strategy for the rapid separation of monophosphorylated from multiply phosphorylated peptides. Mol. Cell Proteomics, 2008, 7(4), 661-671.
60. Thingholm, T.E.; Jensen, O.N. and Larsen, M.R. Enrichment and separation of mono-and multiply phosphorylated peptides using sequential elution from IMAC prior to mass spectrometric analysis. Methods Mol. Biol., 2009, 527, 67-78, xi.
61. Gruhler, A.; Schulze, W.X.; Matthiesen, R.; Mann, M. and Jensen, O.N. Stable isotope labeling of Arabidopsis thaliana cells and quantitative proteomics by mass spectrometry. Mol. Cell Pro-teomics, 2005, 4(11), 1697-1709.
62. Ye, J.; Zhang, X.; Young, C.; Zhao, X.; Hao, Q.; Cheng, L. and Jensen, O.N. Optimized IMAC-IMAC protocol for phosphopep-tide recovery from complex biological samples. J. Proteome Res., 2010, 9(7), 3561-3573.
63. Sugiyama, N.; Masuda, T.; Shinoda, K.; Nakamura, A.; Tomita, M. and Ishihama, Y. Phosphopeptide enrichment by aliphatic hy-droxy acid-modified metal oxide chromatography for nano-LC-MS/MS in proteomics applications. Mol. Cell Proteomics, 2007, 6(6), 1103-1109.
64. Zhou, H.; Albuquerque, C.P.; Liang, J.; Suhandynata, R.T. and Weng, S. Quantitative phosphoproteomics: New technologies and applications in the DNA damage response. Cell Cycle, 2010, 9, 3479-3484.
65. Schaab, C. Analysis of phosphoproteomics data. Methods Mol. Biol., 2011, 696, 41-57.
66. López, E.; Muñoz, S.; Pascual, J. and Madero, L. Relevant phos phoproteomic and mass spectrometry: Approaches useful in clinical research. Clin. Transl. Med., 2012, doi: 10.1186/2001-1326-1-2
67. Lopez, E.; Madero, L.; Lopez-Pascual, J. and Latterich, M. Clinical proteomics and omics clues useful in translational medicine research. Proteome Sci., 2012, 10, doi: 10.1186/1477-5956-10-35.
68. Cho, W.C. and Cheng, C.H. Oncoproteomics: Current trends and future perspectives. Expert Rev. Proteomics, 2007, 4, 401-410.
69. López, E.; Wang, X.; Madero, L.; Pascual, J.L. and Latterich, M. Functional phosphoproteomic mass spectrometry-based approaches. Clin. Transl.Med., 2012, 1, 20.
70. López, E. and Cho, W.C. Phosphoproteomics and Lung Cancer Research. Int. J. Mol. Sci., 2012, 13(10), 12287-12314.
71. Lopez, E.; Cuadrado, C.; Burbano, C.; Jimenez, M.A.; Rodriguez, J. and Crespo, J. Effects of Autoclaving and High Pressure On Al-lergenicity of Hazelnut Proteins. J. Clin. Bioinforma, 2012, 2(1), 12.
72. López, E.; Matthiessen, R.; López, I.; Ashman, K.; Mendieta, J.; Wesselink, J. J.; Gómez-Puertas, P. and Ferreira, A. Functional Phosphoproteomics Tools for Current Immunological Disorders Research. J. Integr. Omics, 2011, 1(1), 1-16.
73. Ashman, K. and Villar, E.L. Phosphoproteomics and cancer research. Clin. Transl. Oncol., 2009, 11(6), 356-362.
74. López-Villar, I.; Ayala, R.; Wesselink, J.; Morillas, J.D.; López, E.; Marín, J.C.; Díaz-Tasende, J.; González, S.; Robles, L. and Martínez-López, J. Simplifying the detection of MUTYH mutations by high resolution melting analysis. BMC Cancer, 2010, 10, 408.
75. López, E.; Monteoliva, L.; Larsen, M.R.; Sachon, E.; Shabaz, M.; Pardo, M.; Pla, J.; Gil, C.; Roepstorff, P. and Nombela, C. Genetic and proteomic evidence supports cell surface localization for yeast enolase. Proteomics, 2006, 6(Suppl 1), 107-118.
76. Anderson, N.L. and Anderson, N.G. Proteome and proteomics: new technologies, new concepts, and new words. Electrophoresis, 1998, 19(11), 1853-1861.
77. Blackstock, W.P. and Weir, M.P. Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol., 1999, 17(3), 121-127.
78. James, P. Protein identification in the post-genome era: the rapid rise of proteomics. Quart. Rev. Biophys., 1997, 30(4), 279-331.
79. Ray, S.; Reddy, P.J.; Choudhary, S.; Raghu, D. and Srivastava, S. Emerging nanoproteomics approaches for disease biomarker detection: A current perspective. J. Proteomics, 2011, 74(12), 2660-2681.
80. Pan, S.; Chen, R.; Brand, R.E.; Hawley, S.; Tamura, Y.; Gafken, P.R.; Milless, B.P.; Goodlett, D.R.; Rush, J. and Brentnall, T.A. Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study. J. Proteom. Res., 2012, 11(3), 1937-1948. doi: 10.1021/pr201117w.
81. Adams, F.; Gijbels, R. and Van Grieken, R. Inorganic Mass Spec trometry, Wiley, New York, 1988.
82. Bush, K.L. and Lehman T.A. Guide to Mass Spectrometry, VCH Publishers, New York, 1995.
83. Marshall, A.G. and Verdum, F.T. Fourier Transform in NMR, Optical and Mass Spectrometry, Elsevier, Amsterdam 1990.
84. Williams R. Spectroscopy and the Fourier Transform: an interac tive Tutorial, VCH, New York, 1995.
85. Moorhouse, M.J. and Sharma, H.S. Recent advances in i-Gene tools and analysis: microarrays, next generation sequencing and mass spectrometry. Indian J. Biochem. Biophys., 2011, 48(4), 215-225.
86. Carbonnelle, E. and Nassif, X. Applications of MALDI-TOF-MS in clinical microbiology laboratory. Med. Sci. (Paris)., 2011, 27(10), 882-888.
87. Tsybin, Y.O.; Fornelli, L.; Kozhinov, A.N.; Vorobyev, A. and Miladinovic, S.M. High-resolution and tandem mass spectrome-try--the indispensable tools of the XXI century. Chimia (Aarau)., 2011, 65(9), 641-645.
88. Allmer, J. Algorithms for the de novo sequencing of peptides from tandem mass spectra. Expert Rev. Proteomics, 2011, 8(5), 645-657.
89. Vestal, M.L. The future of biological mass spectrometry. J. Am. Soc. Mass Spectrom., 2011, 22(6), 953-959.
90. Caprioli, R.M.; Malorni, A. and Sindona, G. Mass Spectrometry in the Biomolecular Sciences, Kluwer Academic, Dordrecht, 1996.
91. Gaskell, S. J. Mass Spectrometry in Biomedical Research, Wiley, Chchester, 1986.
92. Waller, G.R. Biochemical Applications of Mass Spectrometry, Wiley, New York, 1972.
93. McLafferty, F. W. and Turecek, F. Interpretation of Mass Spectra, University Science Books; 4th edition 1993.
94. Zimmer, J.S.D.; Monroe, M.E.; Qian, W.J. and Smith, R.D. Advances in Proteomics Data Analysis and Display Using an Accu rate Mass Time Tag Approach. Mass Spectrom. Rev., 2006, 25(3), 450-482.
95. Taylor, C.F.; Paton, N.W.; Lilley, K.S.; Binz, P.A.; Julian, R.K. Jr.; Jones, A.R.; Zhu, W.; Apweiler, R.; Aebersold, R.; Deutsch, E.W.; Dunn, M.J.; Heck, A.J.; Leitner, A.; Macht, M.; Mann, M.; Martens, L.; Neubert, T.A.; Patterson, S.D.; Ping, P.; Seymour, S.L.; Souda, P.; Tsugita, A.; Vandekerckhove, J.; Vondriska, T.M.; Whitelegge, J.P.; Wilkins, M.R.; Xenarios, I.; Yates, J.R. 3rd. and Hermjakob, H. The minimum information about a pro-teomics experiment (MIAPE). Nat. Biotechnol., 2007, 25(8), 887-893.
96. Karas, M. and Hillenkamp, F. Laser Desorption Ionization of Proteins with Molecular Masses exceeding 10 000 Daltons. Anal. Chem., 1988, 60, 2299-2301.
97. Tanaka, K.; Waki, H.; Ido, Y.; Akita, S.; Yoshida, Y. and Yo shida, T. Protein and Polymer Analyses up to m/z 100,000 by Laser Ionization Time-of-flight Mass Spectrometry. Rapid Commun. Mass Spectrom., 1988, 2, p151.
98. Zenobi, R. and Knochenmuss, R. Ion Formation in MALDI Mass Spectrometry. Mass Spectrom. Rev., 1998, 17, 337-366.
99. Reflex II (Bruker) User's Guide, 1995, Bruker-Franzen Analytik GMBH, Bremen.
100. Hillenkamp, F.; Karas, M.; Beavis, R.C. and Chait, B.T. Matrix-Assistede Laser Desorption/Ionization Mass Spectrometry of Bio-polymers. Anal. Chem., 1991, 63(24), 1194A-1201A.
101. Karas, M. and Krüger, R. Ion Formation in MALDI: The Cluster Ionization Mechanism. Chem. Rev., 2003, 103, 427-439.
102. Hoffmann, E. De. and Stroobant, S, Mass Spectrometry, Principles and Applications. Book John Wiley & Sons, Ltd, 2001, Second Edition.
103. Yamashita, M. and Fenn, J.B. Electrospray Ion Source. Another Variation on the Free-Jet Theme. J. Phys. Chem., 1984, 88, 4451-4459.
104. Fenn, J.B.; Mann, M.; Meng, C.K.; Wong, S.F. and Whitehouse, C.M. Electrospray Ionization for Mass Spectrometry of Large Biomolecules. Science, 1989, 246, 64-72.
105. Cech, N.B. and Enke, C.G. Practical Implications of Some Recent Studies in Electrospray Ionization Fundamentals. Mass Spec-trometry Rev., 2001, 20, 362-387.
106. Dole, M.; Mack, L.L.; Hines, R.L.; Mobley, R.C.; Ferguson, L.D. and Alice, M.B. Molecular Beams of Macroions. J. Chem. Phys., 1968, 49(5), 2240-2249.
107. Iribarne, J.V. and Thomson, B.A. On the evaporation of small ions from charged droplets. J. Chem. Phys., 1976, 64(6), 2287-2294.
108. Thingholm, T.E. Stem cells, Proteomics and Mass Spectrometry. Master Thesis, PR Group, Odense University of Denmark 2005. 1: 1-198 (www.bmb.sdu.dk)
109. Hernández-Borges, J.; Borges-Miquel, T.M.; Rodríguez-Delgado, M.A. and Cifuentes, A. Sample treatments prior to capillary elec-trophoresis-mass spectrometry. J. Chromatogr. A., 2007, 1153(1-2), 214-226.
110. Guilak, F.; Alexopoulos, L.G.; Haider, M.A.; Ting-Beall, H.P. and Setton, L.A. Zonal uniformity in mechanical properties of the chondrocyte pericellular matrix: micropipette aspiration of canine chondrons isolated by cartilage homogenization. Ann. Biomed. Eng., 2005, 33(10), 1312-1318.
111. Bodzon-Kulakowska, A.; Bierczynska-Krzysik, A.; Dylag, T.; Drabik, A.; Suder, P.; Noga, M.; Jarzebinska, J. and Silberring, J. Methods for samples preparation in proteomic research. J. Chro-matogr. B. Analyt. Technol. Biomed. Life Sci., 2007, 849(1-2), 1-31.
112. Rabilloud, T. Solubilization of proteins for electrophoretic analyses. Electrophoresis, 1996, 17(5), 813-829.
113. Cañas, B.; Piñeiro, C.; Calvo, E.; López-Ferrer, D. and Gallardo, J.M. Trends in sample preparation for classical and second generation proteomics. J. Chromatogr. A., 2007, 1153(1-2), 235-258.
114. Görg, A.; Weiss, W. and Dunn, M.J. Current two-dimensional electrophoresis technology for proteomics. Proteomics, 2004, 4(12), 3665-3685.
115. Oliveira, A.I.; Jerónimo, C. and Henrique, R. Moving forward in bladder cancer detection and diagnosis: the role of epigenetic biomarkers. Expert. Rev. Mol. Diagn., 2012, 12(8), 871-878.
116. Pritchard, J.R.; Bruno, P.M.; Hemann, M.T. and Lauffenburger, D.A. Predicting cancer drug mechanisms of action using molecu lar network signatures. Mol. Biosyst., 2013 Jan 4. [Epub ahead of print]
117. Kang, J.; Lee, H.B.; Cha, J.H.; Hur, H.; Min, B.S.; Baik, S.H.; Kim, N.K.; Sohn, S.K. and Lee, K.Y. Feasibility and Impact on Surgical Outcomes of Modified Double-Stapling Technique for Patients Undergoing Laparoscopic Anterior Resection. J. Gastro-intest. Surg., 2013 Epub ahead of print.
118. Ghai, V.; Sharma, K.; Abbi, K.K.; Shimko, S. and Epner, E.M. Current approaches to epigenetic therapy for the treatment of mantle cell lymphoma. Adv. Exp. Med. Biol., 2013, 779, 257-266.
119. Paules, M.; Casey, M.; Williams, G.; Swann, R.S.; Murphy, P.S.; Salazar, V.M.; Foose, D.; Bailey, B. and Therasse, P. Recommendations for capture, validation and summarisation of data from studies using RECIST. Eur. J. Cancer, 2011, 47(5), 697-701.
120. Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R.; Dancey, J.; Arbuck, S.; Gwyther, S.; Mooney, M.; Rubinstein, L.; Shankar, L.; Dodd, L.; Kaplan, R.; Lacombe, D. and Verweij, J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer, 2009, 45(2), 228-247.
121. Basu, S. and Nair, N. Is it time to incorporate quantitative functional imaging data, FDG PET in particular, into the response evaluation criteria in solid tumours? Nucl. Med. Commun., 2006, 27(5), 413-416.
122. Scher, H.I.; Halabi, S.; Tannock, I.; Morris, M.; Sternberg, C.N.; Carducci, M.A.; Eisenberger, M.A.; Higano, C.; Bubley, G.J.; Dreicer, R.; Petrylak, D.; Kantoff, P.; Basch, E.; Kelly, W.K.; Figg, W.D.; Small, E.J.; Beer, T.M.; Wilding, G.; Martin, A. and Hussain, M. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol., 2008, 26(7), 1148-1159.
123. Cheson, B.D. The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol. Oncol. Clin. North Am., 2007, 21(5), 841-854.
124. Padhani, A.R. and Miles, K.A. Multiparametric imaging of tumor response to therapy. Radiology, 2010, 256(2), 348-364.
125. Michaelis, L.C. and Ratain, M.J. Measuring response in a post-RECIST world: from black and white to shades of grey. Nat. Rev. Cancer, 2006, 6(5), 409-414.
126. Jaffe, C.C. Response assessment in clinical trials: implications for sarcoma clinical trial design. Oncologist, 2008, 13(Suppl 2), 14-18.
127. Armato, 3rd S.G.; Meyer, C.R.; McNitt-Gray, M.F.; McLennan, G.; Reeves, A.P.; Croft, B.Y.; Clarke, L.P. and Rider Research Group. The Reference Image Database to Evaluate Response to therapy in lung cancer (RIDER) project: a resource for the development of change-analysis software. Clin. Pharmacol. Ther., 2008, 84(4), 448-456.
128. Mehrara, E.; Forssell-Aronsson, E. and Bernhardt, P. Objective assessment of tumour response to therapy based on tumour growth kinetics. Br. J. Cancer, 2011, 105(5), 682-686.
129. Sharma, M.R.; Karrison, T.G.; Jin, Y.; Bies, R.R.; Maitland, M.L.; Stadler, W.M. and Ratain, M.J. Resampling phase III data to assess phase II trial designs and endpoints. Clin. Cancer Res., 2012, 18(8), 2309-2315.
130. Hwang, S.I.; Thumar, J.; Lundgren, D.H.; Rezaul, K.; Mayya, V.; Wu, L.; Eng, J.; Wright, M.E. and Han, D.K. Direct cancer tissue proteomics: a method to identify candidate cancer biomarkers from formalin-fixed-paraffin embedded archival issues. Oncogene, 2007, 26(1), 65-76.
131. Rajagopal, M.U.; Hathout, Y.; MacDonald, T.J.; Kieran, M.W.; Gururangan, S.; Blaney, S.M.; Phillips, P.; Packer, R.; Gordish-Dressman, H. and Rood, B.R. Proteomic profiling of cerebrospi-nal fluid identifies prostaglandin D2 synthase as a putative bio-marker for pediatric medulloblastoma: A pediatric brain tumor consortium Study. Proteomics, 2011, 11(5), 935-943. doi: 10.1002/pmic.201000198)
132. Holland, M.; Castro, F.V.; Alexander, S.; Smith, D.; Liu, J.; Walker, M.; Bitton, D.; Mulryan, K.; Ashton, G.; Blaylock, M.; Bagley, S.; Connolly, Y.; Bridgeman, J.; Miller, C.; Krishnan, S.; Dempsey, C.; Masurekar, A.; Stern, P.; Whetton, A. and Saha, V. RAC2,AEP, and ICAM1 expression are associated with CNS dis ease in a mouse model of pre-B childhood acute lymphoblastic leukemia, Blood, 2011, 118, 638-649.
133. Walgren, J.L. and Thompson, D.C. Application of proteomic technologies in the drug development process. Toxicol. Lett., 2004, 149(1-3), 377-385
134. Asano, T.; Yao, Y.; Shin, S.; McCubrey, J.; Abbruzzese, J.L. and Reddy, S.A. Insulin receptor substrate is a mediator of phosphoi-nositide 3-kinase activation in quiescent pancreatic cancer cells. Cancer Res., 2005, 65(20), 9164-9168.
135. Bleicher, K.H.; Böhm, H.J.; Müller, K.; Alanine, A.I. Hit and lead generation: beyond high-throughput screening. Nat. Rev. Drug Discov., 2003, 2(5), 369-378.
136. Cai, X.H.; Zhang, Q.; Shi, S.Y. and Ding, D.F. Searching for potential drug targets in two-component and phosphorelay signal-transduction systems using three-dimensional cluster analysis. Acta Biochim. Biophys. Sin. (Shanghai)., 2005, 37(5), 293-302.
137. Frank, R. and Hargreaves, R. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov., 2003, 2(7), 566-580.
138. Turchi, S.; Mercuri, A.; Lazzerini, G.; Chiesa, M.R.; Musacchio, L.; Tozzi, S.; Boni, M.; Zirilli, O. and Andreassi, M.G. Liquid nitrogen biobank: a resource for biomedical research. Recenti. Prog. Med., 2012, 103(9), 307-312.
139. Jackson, D.H. and Banks, R.E. Banking of clinical samples for proteomic biomarker studies: a consideration of logistical issues with a focus on pre-analytical variation. Proteomics Clin. Appl., 2010, 4(3), 250-270.
140. Inczédy-Farkas, G.; Benkovits, J.; Balogh, N.; Almos, P.; Scholtz, B.; Zahuczky, G.; Török, Z.; Nagy, K.; Réthelyi, J.; Makkos, Z.; Kassai-Farkas, A.; Egerházy, A.; Tuzko, J.; Janka, Z.; Bitter, I.; Németh, G.; Nagy, L. and Molnár, M.J. SCHIZOBANK-The Hungarian national schizophrenia biobank and its role in schizophrenia research and in personalized medicine. Orv. Hetil., 2010; 151(35), 1403-1408.
141. Baker, E.S.; Liu, T.; Petyuk, V.A.; Burnum-Johnson, K.E.; Ibrahim, Y.M.; Anderson, G.A. and Smith, R.D. Mass spectrometry for translational proteomics: progress and clinical implications. Genome Med., 2012, 4(8), 63.
142. Herget-Rosenthal, S.; Metzger, J.; Albalat, A.; Bitsika, V. and Mischak, H. Proteomic biomarkers for the early detection of acute kidney injury. Prilozi, 2012, 33(1), 27-48.
143. Atiomo, W.; Khalid, S.; Parameshweran, S.; Houda, M. and Layfield, R. Proteomic biomarkers for the diagnosis and risk stratification of polycystic ovary syndrome: a systematic review. BJOG, 2009, 116(2), 137-143.
144. Benevento, M. and Munoz, J. Role of mass spectrometry-based proteomics in the study of cellular reprogramming and induced pluripotent stem cells. Expert Rev. Proteomics, 2012, 9(4), 379-399.
145. Stoevesandt, O. and Taussig, M.J. Affinity proteomics: the role of specific binding reagents in human proteome analysis. Expert Rev. Proteomics, 2012, 9(4), 401-414.
146. Ang, J.E.; Kaye, S. and Banerji, U. Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials. Curr. Drug Targets, 2012, [Epub ahead of print]
147. Khan, A.R. and Awan, F.R. Review: Mining of protein based biomarkers for type 2 diabetes mellitus. Pak J. Pharm. Sci., 2012, 25(4), 889-901.
148. Segarra-Medrano, A.; Carnicer-Cáceres, C.; Arbós-Via, M.A.; Quiles-Pérez, M.T.; Agraz-Pamplona, I. and Ostos-Roldán, E. Biological markers of nephrotic syndrome: a few steps forward in the long way. Nefrologia, 2012, 32(5), 558-572.
149. Truong, M.; Yang, B. and Jarrard, D. Towards the Detection of Prostate Cancer in Urine: A Critical Analysis. J. Urol., 2012, pii: S0022-5347(12)04963-4.
150. Shah, F.D.; Begum, R.; Vajaria, B.N.; Patel, K.R.; Patel, J.B.; Shukla, S.N. and Patel, P.S. A review on salivary genomics and proteomics biomarkers in oral cancer. Indian J. Clin. Biochem., 2011, 26(4), 326-334.
151. Engelke, R.; Becker, A.C. and Dengjel, J. The degradative inven tory of the cell: proteomic insights. Antioxid. Redox Signal., 2012, 17(5), 803-812.
152. Thongboonkerd, V. The variability in tissue proteomics. Pro-teomics Clin. Appl., 2012 6(7-8), 340-342.
153. Calvo, K.R.; Liotta, L.A. and Petricoin, E.F. Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy. Biosci. Rep., 2005, 25(1-2), 107-125.
154. Dietel, M. and Sers, C. Personalized medicine and development of targeted therapies: The upcoming challenge for diagnostic molecular pathology. A review. Virchows Arch., 2006, 448(6), 744-755.
155. Azad, N.S.; Rasool, N.; Annunziata, C.M.; Minasian L.; Whiteley, G. and Kohn, E.C. Proteomics in clinical trials and practice: present uses and future promise. Mol. Cell Proteomics, 2006, 5(10), 1819-1829.
156. Nebert, D.W. and Vesell, E.S. Can personalized drug therapy be achieved? A closer look at pharmaco-metabonomics. Trends Pharmacol. Sci., 2006, 27(11), 580-586.
157. Nunn, A.D. Molecular imaging and personalized medicine: an uncertain future Cancer. Biother. Radiopharm., 2007, 22(6), 722-739.
158. Palanichamy, K. and Chakravarti, A. Combining drugs and radiotherapy: from the bench to the bedside. Curr. Opin. Neurol., 2009, 22(6), 625-632.
159. Tan, D.S.; Thomas, G.V.; Garrett, M.D.; Banerji, U.; de Bono, J.S.; Kaye, S.B. and Workman, P. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J., 2009, 15(5), 406-420.
160. Gonzalez-Angulo, A.M.; Hennessy, B.T. and Mills, G.B. Future of personalized medicine in oncology: a systems biology approach. J. Clin. Oncol., 2010, 28(16), 2777-2783.
161. Lee, J.M. and Kohn, E.C. Proteomics as a guiding tool for more effective personalized therapy. Ann. Oncol., 2010, 21(Suppl 7), 205-210.
162. Blum, H.E. Personalized medicine. Praxis (Bern 1994). 2011, 100(3), 159-166.
163. Galvão, E.R.; Martins, L.M.; Ibiapina, J.O.; Andrade, H.M. and Monte, S.J. Breast cancer proteomics: a review for clinicians. J. Cancer Res. Clin. Oncol., 2011, 137(6), 915-925.
164. Berg, D.; Malinowsky, K.; Reischauer, B.; Wolff, C. and Becker, K.F. Use of formalin-fixed and paraffin-embedded tissues for diagnosis and therapy in routine clinical settings. Methods Mol. Biol., 2011, 785, 109-122.
165. Kondo, T. Proteomics for biomarker developmeandnt toward personalized medicine. Rinsho Byori., 2012, 60(7), 644-649.
166. Patel, A.A.; Gilbertson, J.R.; Showe, L.C.; London, J.W.; Ross, E.; Ochs, M.F.; Carver, J.; Lazarus, A.; Parwani, A.V.; Dhir, R.; Beck, J.R.; Liebman, M.; Garcia, F.U.; Prichard, J.; Wilkerson, M.; Herberman, R.B. and Becich, M.J. A novel cross-disciplinary multi-institute approach to translational cancer research: lessons learned from Pennsylvania Cancer Alliance Bioinformatics Consortium (PCABC). Cancer Inform., 2007, 3, 255-274.
167. Cao, Y.; Wang, N.; Ying, X.; Li, A.; Wang, H.; Zhang, X. and Li, W. BioSunMS: a plug-in-based software for the management of patients information and the analysis of peptide profiles from mass spectrometry. BMC Med. Inform. Decis. Mak., 2009, 9, 13.
168. rd. and Rodriguez, H. Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam principles). Proteomics Clin. Appl., 2011, 5(11-12), 580-589.
169. Garay, J.P. and Gray, J.W. Omics and therapy-a basis for precision medicine. Mol. Oncol., 2012, 6(2), 128-139.
170. John, T.A. A comparison of basic and state-of-the-arts skills sets of biomedical science technical staff in Lagos public universities. Afr. J. Med. Sci., 2011, 40(4), 327-337.
171. Reker, D. and Malmström, L. Bioinformatic challenges in targeted proteomics. J. Proteome Res., 2012, 11(9), 4393-4402.
172. Choi, H.; Liu, G.; Mellacheruvu, D.; Tyers, M.; Gingras, A.C. and Nesvizhskii, A.I. Analyzing Protein-Protein Interactions from Affinity Purification-Mass Spectrometry Data with SAINT. Curr. Protoc. Bioinformatics, 2012, Chapter 8: Unit 8.15
173. Rodriguez, H. Restructuring proteomics to enable personalised cancer care. Summer 09. Henry Rodriguez. 2009, 1: 1-1. http://www.ddw-online.com/enabling-technologies/p146757restructuring-proteomics-to-enable-personalised-cancer-care-summer-09.html
174. Boja, E.S. and Rodriguez, H. The path to clinical proteomics research: integration of proteomics, genomics, clinical laboratory and regulatory science. Korean J. Lab Med., 2011, 31(2), 61-71.
175. Boja, E.S. and Rodriguez, H. Mass spectrometry-based targeted quantitative proteomics: achieving sensitive and reproducible detection of proteins. Proteomics, 2012, 12(8), 1093-1110.
176. Vidal, M.; Chan, D.W.; Gerstein, M.; Mann, M.; Omenn, G.S.; Tagle, D. and Sechi, S. The human proteome-a scientific opportunity for transforming diagnostics, therapeutics, and healthcare.; Workshop Participants. Clin. Proteomics, 2012, 9(1), 6.